{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:41:47Z","timestamp":1778802107490,"version":"3.51.4"},"publisher-location":"Singapore","reference-count":117,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811525162","type":"print"},{"value":"9789811525179","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-981-15-2517-9_8","type":"book-chapter","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T13:18:26Z","timestamp":1585919906000},"page":"297-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drug Discovery for Coronary Artery Disease"],"prefix":"10.1007","author":[{"given":"Qing","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zekun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingyan","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJMc1611289","volume":"375","author":"NA Alvarez-Villalobos","year":"2016","unstructured":"Alvarez-Villalobos NA, Trevino-Alvarez AM, Gonzalez-Gonzalez JG (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:1797\u20131798. \nhttps:\/\/doi.org\/10.1056\/NEJMc1611289","journal-title":"N Engl J Med"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai H et al (2017) Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 261:144\u2013152. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.032","journal-title":"Atherosclerosis"},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature22978","volume":"547","author":"E Bassat","year":"2017","unstructured":"Bassat E et al (2017) The extracellular matrix protein agrin promotes heart regeneration in mice. Nature 547:179\u2013184. \nhttps:\/\/doi.org\/10.1038\/nature22978","journal-title":"Nature"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1164680","volume":"324","author":"O Bergmann","year":"2009","unstructured":"Bergmann O et al (2009) Evidence for cardiomyocyte renewal in humans. Science 324:98\u2013102. \nhttps:\/\/doi.org\/10.1126\/science.1164680","journal-title":"Science"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.cell.2015.05.026","volume":"161","author":"O Bergmann","year":"2015","unstructured":"Bergmann O et al (2015) Dynamics of cell generation and turnover in the human heart. Cell 161:1566\u20131575. \nhttps:\/\/doi.org\/10.1016\/j.cell.2015.05.026","journal-title":"Cell"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL et al (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380:11\u201322. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1812792","journal-title":"N Engl J Med"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","volume":"18","author":"O Bilen","year":"2016","unstructured":"Bilen O, Ballantyne CM (2016) Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep 18:61. \nhttps:\/\/doi.org\/10.1007\/s11883-016-0611-4","journal-title":"Curr Atheroscler Rep"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI77139","volume":"125","author":"J Bjorkqvist","year":"2015","unstructured":"Bjorkqvist J et al (2015) Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Investig 125:3132\u20133146. \nhttps:\/\/doi.org\/10.1172\/JCI77139","journal-title":"J Clin Investig"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","volume":"138","author":"EA Bohula","year":"2018","unstructured":"Bohula EA et al (2018) Inflammatory and cholesterol risk in the FOURIER trial. Circulation 138:131\u2013140. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034032","journal-title":"Circulation"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR Buller","year":"2015","unstructured":"Buller HR et al (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372:232\u2013240. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1405760","journal-title":"N Engl J Med"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2017.04.013","volume":"261","author":"G Camejo","year":"2017","unstructured":"Camejo G (2017) Phase 2 clinical trials with K-877 (pemafibrate): a promising selective PPAR-alpha modulator for treatment of combined dyslipidemia. Atherosclerosis 261:163\u2013164. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.04.013","journal-title":"Atherosclerosis"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387\u20132397. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV et al (2003) the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560\u20132572. \nhttps:\/\/doi.org\/10.1001\/jama.289.19.2560","journal-title":"JAMA"},{"key":"8_CR14","doi-asserted-by":"publisher","unstructured":"Consortium CAD et al (2013) Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45:25\u201333. \nhttps:\/\/doi.org\/10.1038\/ng.2480\n\n (2013)","DOI":"10.1038\/ng.2480"},{"key":"8_CR15","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","volume":"33","author":"E Crossey","year":"2015","unstructured":"Crossey E et al (2015) A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33:5747\u20135755. \nhttps:\/\/doi.org\/10.1016\/j.vaccine.2015.09.044","journal-title":"Vaccine"},{"key":"8_CR16","doi-asserted-by":"crossref","unstructured":"Cui YC et al (2017) Ginsenoside Rb1 protects against ischemia\/reperfusion-induced myocardial injury via energy metabolism regulation mediated by RhoA signaling pathway. Sci Rep 7","DOI":"10.1038\/srep44579"},{"key":"8_CR17","doi-asserted-by":"publisher","unstructured":"Murray CJ, GBD et al (2015) Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990\u20132013: quantifying the epidemiological transition. Lancet 386:2145\u20132191. \nhttps:\/\/doi.org\/10.1016\/s0140-6736(15)61340-x","DOI":"10.1016\/s0140-6736(15)61340-x"},{"key":"8_CR18","doi-asserted-by":"publisher","DOI":"10.1089\/jmf.2018.0002","author":"S Davinelli","year":"2018","unstructured":"Davinelli S et al (2018) Cardioprotection by cocoa polyphenols and omega-3 fatty acids: a disease-prevention perspective on aging-associated cardiovascular risk. J Med Food. \nhttps:\/\/doi.org\/10.1089\/jmf.2018.0002","journal-title":"J Med Food"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/ATVBAHA.116.307308","volume":"36","author":"MK Delaney","year":"2016","unstructured":"Delaney MK et al (2016) Differential roles of the NADPH-Oxidase 1 and 2 in platelet activation and thrombosis. Arterioscler Thromb Vasc Biol 36:846\u2013854. \nhttps:\/\/doi.org\/10.1161\/ATVBAHA.116.307308","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1074\/jbc.M114.597229","volume":"290","author":"B Dong","year":"2015","unstructured":"Dong B, Li H, Singh AB, Cao A, Liu J (2015) Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1alpha protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem 290:4047\u20134058. \nhttps:\/\/doi.org\/10.1074\/jbc.M114.597229","journal-title":"J Biol Chem"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"017","DOI":"10.1038\/s41598-017-00042-w","volume":"7","author":"Z Dong","year":"2017","unstructured":"Dong Z et al (2017) Astragaloside IV alleviates heart failure via activating PPARalpha to switch glycolysis to fatty acid beta-oxidation. Sci Rep 7:017\u201302360","journal-title":"Sci Rep"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","volume":"377","author":"D Erlinge","year":"2017","unstructured":"Erlinge D et al (2017) Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med 377:1132\u20131142. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1706443","journal-title":"N Engl J Med"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1111\/jcmm.12883","volume":"20","author":"G Fan","year":"2016","unstructured":"Fan G et al (2016) Danshensu alleviates cardiac ischaemia\/reperfusion injury by inhibiting autophagy and apoptosis via activation of mTOR signalling. J Cell Mol Med 20:1908\u20131919. \nhttps:\/\/doi.org\/10.1111\/jcmm.12883","journal-title":"J Cell Mol Med"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fphar.2018.00214","volume":"9","author":"R Feng","year":"2018","unstructured":"Feng R et al (2018) Gut microbiota-regulated pharmacokinetics of berberine and active metabolites in beagle dogs after oral administration. Front Pharmacol 9:214. \nhttps:\/\/doi.org\/10.3389\/fphar.2018.00214","journal-title":"Front Pharmacol"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K et al (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376:41\u201351. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1609243","journal-title":"N Engl J Med"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ncpcardio1211","volume":"5","author":"U Forstermann","year":"2008","unstructured":"Forstermann U (2008) Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 5:338\u2013349. \nhttps:\/\/doi.org\/10.1038\/ncpcardio1211","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"8_CR27","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376:2300\u20132302. \nhttps:\/\/doi.org\/10.1056\/NEJMc1701990","journal-title":"N Engl J Med"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart JC (2017) Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 16:124. \nhttps:\/\/doi.org\/10.1186\/s12933-017-0602-y","journal-title":"Cardiovasc Diabetol"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D et al (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373:438\u2013447. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1400283","journal-title":"N Engl J Med"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP et al (2017) Cognitive function in a randomized trial of evolocumab. N Engl J Med 377:633\u2013643. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1701131","journal-title":"N Engl J Med"},{"key":"8_CR31","doi-asserted-by":"publisher","unstructured":"Group SR et al (2015) A Randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103\u20132116. \nhttps:\/\/doi.org\/10.1056\/nejmoa1511939\n\n (2015)","DOI":"10.1056\/nejmoa1511939"},{"key":"8_CR32","doi-asserted-by":"publisher","unstructured":"Group HTRC et al (2017) Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 377:1217\u20131227. \nhttps:\/\/doi.org\/10.1056\/nejmoa1706444","DOI":"10.1056\/nejmoa1706444"},{"key":"8_CR33","doi-asserted-by":"publisher","unstructured":"Group ASC et al (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379:1540\u20131550. \nhttps:\/\/doi.org\/10.1056\/nejmoa1804989\n\n (2018)","DOI":"10.1056\/nejmoa1804989"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/atvbaha.113.302677","volume":"34","author":"MJ Gutierrez","year":"2014","unstructured":"Gutierrez MJ et al (2014) Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 34:676\u2013683. \nhttps:\/\/doi.org\/10.1161\/atvbaha.113.302677","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1161\/CIRCULATIONAHA.116.023027","volume":"135","author":"H Hao","year":"2017","unstructured":"Hao H et al (2017) Loss of endothelial CXCR7 impairs vascular homeostasis and cardiac remodeling after myocardial infarction: implications for cardiovascular drug discovery. Circulation 135:1253\u20131264. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023027","journal-title":"Circulation"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1172\/JCI93868","volume":"127","author":"L He","year":"2017","unstructured":"He L et al (2017) Preexisting endothelial cells mediate cardiac neovascularization after injury. J Clin Investig 127:2968\u20132981. \nhttps:\/\/doi.org\/10.1172\/JCI93868","journal-title":"J Clin Investig"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","volume":"249","author":"N Hennuyer","year":"2016","unstructured":"Hennuyer N et al (2016) The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis 249:200\u2013208. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.03.003","journal-title":"Atherosclerosis"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","volume":"70","author":"MA Hlatky","year":"2017","unstructured":"Hlatky MA, Kazi DS (2017) PCSK9 inhibitors: economics and policy. J Am Coll Cardiol 70:2677\u20132687. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2017.10.001","journal-title":"J Am Coll Cardiol"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1139\/cjpp-2015-0457","volume":"94","author":"H Huang","year":"2016","unstructured":"Huang H, Lai S, Wan Q, Qi W, Liu J (2016) Astragaloside IV protects cardiomyocytes from anoxia\/reoxygenation injury by upregulating the expression of Hes1 protein. Can J Physiol Pharmacol 94:542\u2013553","journal-title":"Can J Physiol Pharmacol"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"O Investigators","year":"2008","unstructured":"Investigators O et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547\u20131559. \nhttps:\/\/doi.org\/10.1056\/NEJMoa0801317","journal-title":"N Engl J Med"},{"key":"8_CR41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3109\/13880209.2010.551776","volume":"49","author":"F Jiang","year":"2011","unstructured":"Jiang F, Qian J, Chen S, Zhang W, Liu C (2011) Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress. Pharm Biol 49:856\u2013863","journal-title":"Pharm Biol"},{"key":"8_CR42","doi-asserted-by":"publisher","unstructured":"Key NS (2014) Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hematology Am Soc Hematology Educ Program 2014:66\u201370. \nhttps:\/\/doi.org\/10.1182\/asheducation-2014.1.66\n\n (2014)","DOI":"10.1182\/asheducation-2014.1.66"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature14582","volume":"523","author":"W Kimura","year":"2015","unstructured":"Kimura W et al (2015) Hypoxia fate mapping identifies cycling cardiomyocytes in the adult heart. Nature 523:226\u2013230. \nhttps:\/\/doi.org\/10.1038\/nature14582","journal-title":"Nature"},{"key":"8_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jacl.2014.09.013","volume":"9","author":"RM Krauss","year":"2015","unstructured":"Krauss RM, Pinto CA, Liu Y, Johnson-Levonas AO, Dansky HM (2015) Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. J Clin Lipidol 9:93\u2013102. \nhttps:\/\/doi.org\/10.1016\/j.jacl.2014.09.013","journal-title":"J Clin Lipidol"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00005344-199001000-00025","volume":"15","author":"CY Kwan","year":"1990","unstructured":"Kwan CY, Daniel EE, Chen MC (1990) Inhibition of vasoconstriction by tetramethylpyrazine: does it act by blocking the voltage-dependent Ca channel? J Cardiovasc Pharmacol 15:157\u2013162","journal-title":"J Cardiovasc Pharmacol"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.taap.2015.06.014","volume":"287","author":"HH Kwok","year":"2015","unstructured":"Kwok HH, Chan LS, Poon PY, Yue PY, Wong RN (2015) Ginsenoside-Rg1 induces angiogenesis by the inverse regulation of MET tyrosine kinase receptor expression through miR-23a. Toxicol Appl Pharmacol 287:276\u2013283","journal-title":"Toxicol Appl Pharmacol"},{"key":"8_CR47","doi-asserted-by":"publisher","unstructured":"Larsson M et al (2014) A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 6:222ra217. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.3006804","DOI":"10.1126\/scitranslmed.3006804"},{"key":"8_CR48","doi-asserted-by":"crossref","unstructured":"Li L et al (2018) Ginsenoside Rg1 ameliorates rat myocardial ischemia-reperfusion injury by modulating energy metabolism pathways. Front Physiol 9","DOI":"10.3389\/fphys.2018.00078"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"015","DOI":"10.1186\/s12967-014-0366-z","volume":"13","author":"XY Li","year":"2015","unstructured":"Li XY et al (2015) Effect of berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med 13:015\u20130629","journal-title":"J Transl Med"},{"key":"8_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/fcp.12232","volume":"31","author":"L Li","year":"2017","unstructured":"Li L, Hou X, Xu R, Liu C, Tu M (2017) Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol 31:17\u201336","journal-title":"Fundam Clin Pharmacol"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.fitote.2016.02.001","volume":"109","author":"CS Liu","year":"2016","unstructured":"Liu CS, Zheng YR, Zhang YF, Long XY (2016) Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia 109:274\u2013282","journal-title":"Fitoterapia"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","volume":"374","author":"EM Lonn","year":"2016","unstructured":"Lonn EM et al (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:2009\u20132020. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1600175","journal-title":"N Engl J Med"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/157016109788340767","volume":"7","author":"JM Lu","year":"2009","unstructured":"Lu JM, Yao Q, Chen C (2009) Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 7:293\u2013302","journal-title":"Curr Vasc Pharmacol"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1440-1681.2011.05628.x","volume":"39","author":"L Lv","year":"2012","unstructured":"Lv L, Jiang SS, Xu J, Gong JB, Cheng Y (2012) Protective effect of ligustrazine against myocardial ischaemia reperfusion in rats: the role of endothelial nitric oxide synthase. Clin Exp Pharmacol Physiol 39:20\u201327","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"8_CR55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137:323\u2013334. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032038","journal-title":"Circulation"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1254\/jjp.83.241","volume":"83","author":"F Mahmoud","year":"2000","unstructured":"Mahmoud F et al (2000) In vitro effects of Ginkgolide B on lymphocyte activation in atopic asthma: comparison with cyclosporin A. Jpn J Pharmacol 83:241\u2013245","journal-title":"Jpn J Pharmacol"},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE et al (2019) Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 380:23\u201332. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1811403","journal-title":"N Engl J Med"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"8_CR59","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","volume":"123","author":"A Matafonov","year":"2014","unstructured":"Matafonov A et al (2014) Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 123:1739\u20131746. \nhttps:\/\/doi.org\/10.1182\/blood-2013-04-499111","journal-title":"Blood"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1194\/jlr.M074880","volume":"58","author":"JS Millar","year":"2017","unstructured":"Millar JS et al (2017) Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E. J Lipid Res 58:1214\u20131220. \nhttps:\/\/doi.org\/10.1194\/jlr.M074880","journal-title":"J Lipid Res"},{"key":"8_CR61","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature22979","volume":"547","author":"Y Morikawa","year":"2017","unstructured":"Morikawa Y, Heallen T, Leach J, Xiao Y, Martin JF (2017) Dystrophin-glycoprotein complex sequesters Yap to inhibit cardiomyocyte proliferation. Nature 547:227\u2013231. \nhttps:\/\/doi.org\/10.1038\/nature22979","journal-title":"Nature"},{"key":"8_CR62","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"8_CR63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035901","author":"BL Neuen","year":"2018","unstructured":"Neuen BL et al (2018) Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS program. Circulation. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035901","journal-title":"Circulation"},{"key":"8_CR64","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ et al (2016) Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316:2373\u20132384. \nhttps:\/\/doi.org\/10.1001\/jama.2016.16951","journal-title":"JAMA"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/ATVBAHA.116.308595","volume":"37","author":"KF Nickel","year":"2017","unstructured":"Nickel KF, Long AT, Fuchs TA, Butler LM, Renne T (2017) Factor XII as a therapeutic target in thromboembolic and inflammatory diseases. Arterioscler Thromb Vasc Biol 37:13\u201320. \nhttps:\/\/doi.org\/10.1161\/ATVBAHA.116.308595","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"8_CR66","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.atherosclerosis.2014.10.099","volume":"237","author":"D Nikolic","year":"2014","unstructured":"Nikolic D, Mikhailidis DP, Davidson MH, Rizzo M, Banach M (2014) ETC-1002: a future option for lipid disorders? Atherosclerosis 237:705\u2013710. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.10.099","journal-title":"Atherosclerosis"},{"key":"8_CR67","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE et al (2016) Efficacy and tolerability of evolocumab versus ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 315:1580\u20131590. \nhttps:\/\/doi.org\/10.1001\/jama.2016.3608","journal-title":"JAMA"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2018.03.019","volume":"272","author":"VM Olkkonen","year":"2018","unstructured":"Olkkonen VM, Sinisalo J, Jauhiainen M (2018) New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk? Atherosclerosis 272:27\u201332. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.03.019","journal-title":"Atherosclerosis"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/blood-2017-05-785253","volume":"132","author":"A Pang","year":"2018","unstructured":"Pang A et al (2018) Shear-induced integrin signaling in platelet phosphatidylserine exposure, microvesicle release, and coagulation. Blood 132:533\u2013543. \nhttps:\/\/doi.org\/10.1182\/blood-2017-05-785253","journal-title":"Blood"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000438945","volume":"96","author":"HX Pei","year":"2015","unstructured":"Pei HX, Hua R, Guan CX, Fang X (2015) Ginkgolide B reduces the degradation of membrane phospholipids to prevent ischemia\/reperfusion myocardial injury in rats. Pharmacology 96:233\u2013239","journal-title":"Pharmacology"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1161\/atvbaha.117.309225","volume":"37","author":"C Perez-Sanchez","year":"2017","unstructured":"Perez-Sanchez C et al (2017) Ubiquinol effects on antiphospholipid syndrome prothrombotic profile: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 37:1923\u20131932. \nhttps:\/\/doi.org\/10.1161\/atvbaha.117.309225","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/ars.2013.5532","volume":"21","author":"D Pietraforte","year":"2014","unstructured":"Pietraforte D et al (2014) Redox control of platelet functions in physiology and pathophysiology. Antioxid Redox Signal 21:177\u2013193. \nhttps:\/\/doi.org\/10.1089\/ars.2013.5532","journal-title":"Antioxid Redox Signal"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.1200708","volume":"331","author":"ER Porrello","year":"2011","unstructured":"Porrello ER et al (2011) Transient regenerative potential of the neonatal mouse heart. Science 331:1078\u20131080. \nhttps:\/\/doi.org\/10.1126\/science.1200708","journal-title":"Science"},{"key":"8_CR74","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M et al (2017) Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 129:1210\u20131215. \nhttps:\/\/doi.org\/10.1182\/blood-2016-09-742262","journal-title":"Blood"},{"key":"8_CR75","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","volume":"558","author":"X Que","year":"2018","unstructured":"Que X et al (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301\u2013306. \nhttps:\/\/doi.org\/10.1038\/s41586-018-0198-8","journal-title":"Nature"},{"key":"8_CR76","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034222","author":"K Radholm","year":"2018","unstructured":"Radholm K et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034222","journal-title":"Circulation"},{"key":"8_CR77","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK et al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376:1430\u20131440. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1615758","journal-title":"N Engl J Med"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","volume":"118","author":"AS Revenko","year":"2011","unstructured":"Revenko AS et al (2011) Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 118:5302\u20135311. \nhttps:\/\/doi.org\/10.1182\/blood-2011-05-355248","journal-title":"Blood"},{"key":"8_CR79","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119\u20131131. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"key":"8_CR80","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker PM et al (2018a) Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391:319\u2013328. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(17)32814-3","journal-title":"Lancet"},{"key":"8_CR81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809798","author":"PM Ridker","year":"2018","unstructured":"Ridker PM et al (2018b) Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1809798","journal-title":"N Engl J Med"},{"key":"8_CR82","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCRESAHA.114.302692","volume":"114","author":"R Roberts","year":"2014","unstructured":"Roberts R (2014) Genetics of coronary artery disease. Circ Res 114:1890\u20131903. \nhttps:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302692","journal-title":"Circ Res"},{"key":"8_CR83","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489\u20131499. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1501031","journal-title":"N Engl J Med"},{"key":"8_CR84","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1500\u20131509. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1500858","journal-title":"N Engl J Med"},{"key":"8_CR85","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713\u20131722. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"8_CR86","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature22034","volume":"544","author":"D Saleheen","year":"2017","unstructured":"Saleheen D et al (2017) Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature 544:235\u2013239. \nhttps:\/\/doi.org\/10.1038\/nature22034","journal-title":"Nature"},{"key":"8_CR87","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2174\/0929867324666170609081612","volume":"25","author":"J Schmitz","year":"2018","unstructured":"Schmitz J, Gouni-Berthold I (2018) APOC-III antisense oligonucleotides: a new option for the treatment of hypertriglyceridemia. Curr Med Chem 25:1567\u20131576. \nhttps:\/\/doi.org\/10.2174\/0929867324666170609081612","journal-title":"Curr Med Chem"},{"key":"8_CR88","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097\u20132107. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"},{"key":"8_CR89","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature11682","volume":"493","author":"SE Senyo","year":"2013","unstructured":"Senyo SE et al (2013) Mammalian heart renewal by pre-existing cardiomyocytes. Nature 493:433\u2013436. \nhttps:\/\/doi.org\/10.1038\/nature11682","journal-title":"Nature"},{"key":"8_CR90","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nature12613","volume":"503","author":"B Shen","year":"2013","unstructured":"Shen B et al (2013) A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature 503:131\u2013135. \nhttps:\/\/doi.org\/10.1038\/nature12613","journal-title":"Nature"},{"key":"8_CR91","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/0003-4819-147-1-200707030-00003","volume":"147","author":"I Sipahi","year":"2007","unstructured":"Sipahi I et al (2007) Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 147:10\u201318","journal-title":"Ann Intern Med"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1161\/CIRCULATIONAHA.118.036210","volume":"138","author":"J Tang","year":"2018","unstructured":"Tang J et al (2018) Fate mapping of sca1(+) cardiac progenitor cells in the adult mouse heart. Circulation 138:2967\u20132969. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036210","journal-title":"Circulation"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"Tg","year":"2014","unstructured":"Tg et al (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371:22\u201331. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1307095","journal-title":"N Engl J Med"},{"key":"8_CR94","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","volume":"10","author":"PD Thompson","year":"2016","unstructured":"Thompson PD et al (2016) Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol 10:556\u2013567. \nhttps:\/\/doi.org\/10.1016\/j.jacl.2015.12.025","journal-title":"J Clin Lipidol"},{"key":"8_CR95","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature13309","volume":"509","author":"JH Berlo van","year":"2014","unstructured":"van Berlo JH et al (2014) c-kit\u2009+\u2009cells minimally contribute cardiomyocytes to the heart. Nature 509:337\u2013341. \nhttps:\/\/doi.org\/10.1038\/nature13309","journal-title":"Nature"},{"key":"8_CR96","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11655-010-0162-4","volume":"16","author":"XD Wang","year":"2010","unstructured":"Wang XD, Gu TX, Shi EY, Lu CM, Wang C (2010) Effect and mechanism of panaxoside Rg1 on neovascularization in myocardial infarction rats. Chin J Integr Med 16:162\u2013166","journal-title":"Chin J Integr Med"},{"key":"8_CR97","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jep.2011.03.070","volume":"135","author":"X Wang","year":"2011","unstructured":"Wang X et al (2011) Differential cardioprotective effects of salvianolic acid and tanshinone on acute myocardial infarction are mediated by unique signaling pathways. J Ethnopharmacol 135:662\u2013671","journal-title":"J Ethnopharmacol"},{"key":"8_CR98","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"8_CR99","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2007.04.005","volume":"120","author":"HJ Wei","year":"2007","unstructured":"Wei HJ et al (2007) Gelatin microspheres encapsulated with a nonpeptide angiogenic agent, ginsenoside Rg1, for intramyocardial injection in a rat model with infarcted myocardium. J Control Release 120:27\u201334","journal-title":"J Control Release"},{"key":"8_CR100","doi-asserted-by":"publisher","unstructured":"Wong PC et al (2017) Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 9. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.aaf5294","DOI":"10.1126\/scitranslmed.aaf5294"},{"key":"8_CR101","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ejphar.2011.10.046","volume":"674","author":"HJ Wu","year":"2012","unstructured":"Wu HJ, Hao J, Wang SQ, Jin BL, Chen XB (2012) Protective effects of ligustrazine on TNF-alpha-induced endothelial dysfunction. Eur J Pharmacol 674:365\u2013369","journal-title":"Eur J Pharmacol"},{"key":"8_CR102","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1111\/jcmm.13557","volume":"22","author":"DM Wu","year":"2018","unstructured":"Wu DM et al (2018) Tanshinone IIA prevents left ventricular remodelling via the TLR4\/MyD88\/NF-kappaB signalling pathway in rats with myocardial infarction. J Cell Mol Med 22:3058\u20133072","journal-title":"J Cell Mol Med"},{"key":"8_CR103","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1136\/gut.2003.024893","volume":"53","author":"Y Yang","year":"2004","unstructured":"Yang Y, Nemoto EM, Harvey SA, Subbotin VM, Gandhi CR (2004) Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut 53:877\u2013883","journal-title":"Gut"},{"key":"8_CR104","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41467-018-05512-x","volume":"9","author":"C Yao","year":"2018","unstructured":"Yao C et al (2018) Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun 9:3268. \nhttps:\/\/doi.org\/10.1038\/s41467-018-05512-x","journal-title":"Nat Commun"},{"key":"8_CR105","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","volume":"123","author":"JW Yau","year":"2014","unstructured":"Yau JW et al (2014) Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123:2102\u20132107. \nhttps:\/\/doi.org\/10.1182\/blood-2013-12-540872","journal-title":"Blood"},{"key":"8_CR106","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00109-011-0723-9","volume":"89","author":"H Yin","year":"2011","unstructured":"Yin H et al (2011) Ginsenoside-Rg1 enhances angiogenesis and ameliorates ventricular remodeling in a rat model of myocardial infarction. J Mol Med 89:363\u2013375","journal-title":"J Mol Med"},{"key":"8_CR107","first-page":"14793","volume":"8","author":"J Yu","year":"2015","unstructured":"Yu J et al (2015) Danshensu protects isolated heart against ischemia reperfusion injury through activation of Akt\/ERK1\/2\/Nrf2 signaling. Int J Clin Exp Med 8:14793\u201314804","journal-title":"Int J Clin Exp Med"},{"key":"8_CR108","doi-asserted-by":"publisher","first-page":"8192383","DOI":"10.1155\/2017\/8192383","volume":"2017","author":"LJ Yu","year":"2017","unstructured":"Yu LJ et al (2017) Salvianolic acid exerts cardioprotection through promoting angiogenesis in animal models of acute myocardial infarction: preclinical evidence. Oxidative Med Cell Longev 2017:8192383. \nhttps:\/\/doi.org\/10.1155\/2017\/8192383","journal-title":"Oxidative Med Cell Longev"},{"key":"8_CR109","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S et al (2016a) Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:2021\u20132031. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1600176","journal-title":"N Engl J Med"},{"key":"8_CR110","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S et al (2016b) Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 374:2032\u20132043. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1600177","journal-title":"N Engl J Med"},{"key":"8_CR111","unstructured":"Zhang S et al (2015) Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-kappaB\/PGC-1alpha signaling mediated energy biosynthesis. PloS one 10"},{"key":"8_CR112","doi-asserted-by":"publisher","first-page":"150272","DOI":"10.1098\/rsob.150272","volume":"6","author":"R Zhang","year":"2016","unstructured":"Zhang R (2016) The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. Open Biol 6:150272. \nhttps:\/\/doi.org\/10.1098\/rsob.150272","journal-title":"Open Biol"},{"key":"8_CR113","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1159\/000324012","volume":"26","author":"Y Zhang","year":"2010","unstructured":"Zhang Y et al (2010) Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes. Cell Physiol Biochem 26:991\u2013998","journal-title":"Cell Physiol Biochem"},{"key":"8_CR114","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1538\/expanim.16-0121","volume":"66","author":"X Zheng","year":"2017","unstructured":"Zheng X et al (2017) Ginsenoside Rb1 improves cardiac function and remodeling in heart failure. Exp Anim 66:217\u2013228","journal-title":"Exp Anim"},{"key":"8_CR115","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.4238\/2015","volume":"14","author":"MX Zhou","year":"2015","unstructured":"Zhou MX, Fu JH, Zhang Q, Wang JQ (2015) Effect of hydroxy safflower yellow A on myocardial apoptosis after acute myocardial infarction in rats. Genet Mol Res 14:3133\u20133141. \nhttps:\/\/doi.org\/10.4238\/2015","journal-title":"Genet Mol Res"},{"key":"8_CR116","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2017.11.023","volume":"268","author":"L Zhu","year":"2018","unstructured":"Zhu L et al (2018) Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe(-\/-) mice. Atherosclerosis 268:117\u2013126. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.023","journal-title":"Atherosclerosis"},{"key":"8_CR117","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373:2117\u20132128. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"}],"container-title":["Advances in Experimental Medicine and Biology","Coronary Artery Disease: Therapeutics and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-15-2517-9_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T13:24:14Z","timestamp":1585920254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-15-2517-9_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9789811525162","9789811525179"],"references-count":117,"URL":"https:\/\/doi.org\/10.1007\/978-981-15-2517-9_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"26 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"This work was supported by the National Natural Science Foundation of China (81570269), Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2017-I2M-1-008, 2016-I2M-1-003\/006), Peking Union Medical College and Chinese Academy of Medical Sciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Sources of Funding"}}]}}